Cargando…

Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients

BACKGROUND: Circulating tumour DNA (ctDNA)-based sequencing might provide a simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to assess the ctDNA sequencing-based tumour mutation index (TMI) model for screening responders (from non-responders) among NSCLC pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jun, Wu, Jun, Lou, Yuqing, Shi, Qin, Xu, Jun, Zhang, Lele, Nie, Wei, Qian, Jie, Wang, Yanan, Zhang, Yanwei, Jiao, Jing, Zhang, Xueyan, Zhang, Wei, Wang, Huimin, Chu, Tianqing, Zhong, Hua, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336041/
https://www.ncbi.nlm.nih.gov/pubmed/35906676
http://dx.doi.org/10.1186/s40364-022-00400-5
_version_ 1784759460029267968
author Lu, Jun
Wu, Jun
Lou, Yuqing
Shi, Qin
Xu, Jun
Zhang, Lele
Nie, Wei
Qian, Jie
Wang, Yanan
Zhang, Yanwei
Jiao, Jing
Zhang, Xueyan
Zhang, Wei
Wang, Huimin
Chu, Tianqing
Zhong, Hua
Han, Baohui
author_facet Lu, Jun
Wu, Jun
Lou, Yuqing
Shi, Qin
Xu, Jun
Zhang, Lele
Nie, Wei
Qian, Jie
Wang, Yanan
Zhang, Yanwei
Jiao, Jing
Zhang, Xueyan
Zhang, Wei
Wang, Huimin
Chu, Tianqing
Zhong, Hua
Han, Baohui
author_sort Lu, Jun
collection PubMed
description BACKGROUND: Circulating tumour DNA (ctDNA)-based sequencing might provide a simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to assess the ctDNA sequencing-based tumour mutation index (TMI) model for screening responders (from non-responders) among NSCLC patients who received monotherapy with docetaxel or atezolizumab. METHODS: We performed a retrospective analysis of the POPLAR (NCT01903993) and OAK (NCT02008227) trials. We identified three biomarkers, blood tumour mutation burden (bTMB), sensitive blood tumour mutation burden (sbTMB) and unfavourable mutation score (UMS), of the ctDNA profiles. After integrating the advantages and disadvantages of the three independent biomarkers, we developed the TMI model and identified NSCLC patients who may benefit from monotherapy with docetaxel or atezolizumab in terms of overall survival (OS). RESULTS: The TMI model as a stratified biomarker for docetaxel responders provided a median OS duration of 5.55 months longer than non-responders in the OAK cohort, with a significantly decreased hazard ratio (HR). Moreover, atezolizumab responders had a 10.21-month OS advantage over atezolizumab non-responders in the OAK cohort via TMI stratification, and the HR was also decreased significantly. The TMI demonstrated effectiveness for stratifying responders in the POPLAR cohort. Importantly, we found that the TMI model could screen additional responders upon combining the cohorts from the POPLAR and OAK trials after adjustment. CONCLUSION: In the present study, we provide a novel TMI model for screening responders (from non-responders) among NSCLC patients who received the 2nd-line monotherapy with docetaxel or atezolizumab. We believe that the biomarker TMI will potentially be effective for the clinical treatment of NSCLC in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-022-00400-5.
format Online
Article
Text
id pubmed-9336041
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93360412022-07-30 Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients Lu, Jun Wu, Jun Lou, Yuqing Shi, Qin Xu, Jun Zhang, Lele Nie, Wei Qian, Jie Wang, Yanan Zhang, Yanwei Jiao, Jing Zhang, Xueyan Zhang, Wei Wang, Huimin Chu, Tianqing Zhong, Hua Han, Baohui Biomark Res Research BACKGROUND: Circulating tumour DNA (ctDNA)-based sequencing might provide a simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to assess the ctDNA sequencing-based tumour mutation index (TMI) model for screening responders (from non-responders) among NSCLC patients who received monotherapy with docetaxel or atezolizumab. METHODS: We performed a retrospective analysis of the POPLAR (NCT01903993) and OAK (NCT02008227) trials. We identified three biomarkers, blood tumour mutation burden (bTMB), sensitive blood tumour mutation burden (sbTMB) and unfavourable mutation score (UMS), of the ctDNA profiles. After integrating the advantages and disadvantages of the three independent biomarkers, we developed the TMI model and identified NSCLC patients who may benefit from monotherapy with docetaxel or atezolizumab in terms of overall survival (OS). RESULTS: The TMI model as a stratified biomarker for docetaxel responders provided a median OS duration of 5.55 months longer than non-responders in the OAK cohort, with a significantly decreased hazard ratio (HR). Moreover, atezolizumab responders had a 10.21-month OS advantage over atezolizumab non-responders in the OAK cohort via TMI stratification, and the HR was also decreased significantly. The TMI demonstrated effectiveness for stratifying responders in the POPLAR cohort. Importantly, we found that the TMI model could screen additional responders upon combining the cohorts from the POPLAR and OAK trials after adjustment. CONCLUSION: In the present study, we provide a novel TMI model for screening responders (from non-responders) among NSCLC patients who received the 2nd-line monotherapy with docetaxel or atezolizumab. We believe that the biomarker TMI will potentially be effective for the clinical treatment of NSCLC in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-022-00400-5. BioMed Central 2022-07-29 /pmc/articles/PMC9336041/ /pubmed/35906676 http://dx.doi.org/10.1186/s40364-022-00400-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lu, Jun
Wu, Jun
Lou, Yuqing
Shi, Qin
Xu, Jun
Zhang, Lele
Nie, Wei
Qian, Jie
Wang, Yanan
Zhang, Yanwei
Jiao, Jing
Zhang, Xueyan
Zhang, Wei
Wang, Huimin
Chu, Tianqing
Zhong, Hua
Han, Baohui
Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients
title Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients
title_full Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients
title_fullStr Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients
title_full_unstemmed Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients
title_short Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients
title_sort blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336041/
https://www.ncbi.nlm.nih.gov/pubmed/35906676
http://dx.doi.org/10.1186/s40364-022-00400-5
work_keys_str_mv AT lujun bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT wujun bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT louyuqing bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT shiqin bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT xujun bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT zhanglele bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT niewei bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT qianjie bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT wangyanan bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT zhangyanwei bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT jiaojing bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT zhangxueyan bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT zhangwei bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT wanghuimin bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT chutianqing bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT zhonghua bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients
AT hanbaohui bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients